Pharmaceutical funding
Five pharmaceutical companies are providing almost £11m in funding to a collaboration that aims to develop new drug treatments.
Five of the world’s leading pharmaceutical companies are providing almost £11m in funding to the Division of Signal Transduction Therapy (DSTT), a collaboration that aims to develop new drug treatments.
AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck KGaA (through its Merck Serono division) and Pfizer will provide core support of £10.8m to the DSTT over the four-year period from 2008-2012.
The DSTT is a collaboration between the pharmaceutical companies and 13 research teams based at Dundee University. Eight of the teams are based within the Medical Research Council’s (MRC) protein phosphorylation unit at the college of life sciences at the university.
The DSTT was founded in 1998 and expanded in 2003, and over that period attracted funding of £23m. It is thought to be the largest collaboration between the UK academic community and the pharmaceutical industry. The new round of funding will secure 50 posts at Dundee University for the next four years.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
WildFusion helps robot traverse difficult terrain
<a...